Trial Profile
Prospective, multi-centric, randomized, open-label, two-arm, parallel group, active control, comparative clinical study to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of R-TPR-007/ Norditropin® Nordilet® in growth hormone deficient children
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2017
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors Reliance Life Sciences
- 21 Aug 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 31 Aug 2016 New trial record